Cisplatin triggers platelet activation

Thrombosis Research

Volumn 99, Issue 5, 2000, Pages 503-509

  Togna, Giuseppina I ^a   Togna, Anna Rita ^a   Franconi, Matteo ^a   Caprino, Luciano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cisplatin; Phospholipases; Platelet; Thromboxane

Indexed keywords

ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CISPLATIN; COLLAGEN; DIAGNOSTIC AGENT; THROMBOXANE B2; TRITIUM;

ARTICLE; BIOSYNTHESIS; DRUG EFFECT; HUMAN; MALE; METABOLISM; THROMBOCYTE ACTIVATION;

ANTINEOPLASTIC AGENTS; ARACHIDONIC ACID; CISPLATIN; COLLAGEN; HUMANS; MALE; PLATELET ACTIVATION; THROMBOXANE B2; TRITIUM;

EID: 0034264523     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00294-2     Document Type: Article

References (38)

1. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-7.
2. Içli F, Karaoguz H, Dinçol D, Demirkazik A, Günel N, Karaoguz R, Üner A. Severe vascular toxicity associated with cisplatin-based chemoterapy. Cancer 1993;72:587-93.
3. Molloy RG, Welch GC, Drury JK, Abel BJ. Arterial thrombosis after chemotherapy with cisplatin, vinblastine and methotrexate. Br J Clin Prat 1995;49:50-1.
4. Lepidini G, Biancari F, D'Andrea V. Severe thrombosis after chemotherapy for metastatic choriocarcinoma of the testis maintaining complete remission for a long period. Scand J Urol Nephrol 1996;31:221-2.
5. Jackson AM, Rose BD, Graff LG, Jacobs JB, Scharwartz JH, Strauss GM, Yang JPS, Rudnick MR, Elfenbein IB, Narins RG. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Internal Med 1984;101:41-4.
6. Fields SM, Lindley CM. Thrombotic microangiopathy associated with chemotherapy: case report and review of the literature. DICP Ann Pharmacotherapy 1989;23:582-7.
7. Blanche P, Wyplosz B, Herry I, Sicard D. Microangiopathie thrombotique après chimioembolisation par cisplatine (letter). Ann Med Intern 1995;146:452.
8. Kukla LJ, McGuire WP, Lad T, Saltiel M. Acute vascular episodes associated with therapy for carcinomas of the upper aerodigestive tract with bleomycin, vincristine and cisplatin. Cancer Treat Rep 1982;66:369-70.
9. Gerl A, Clemm C, Wilmanns W. Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer. Lancet 1991;338:385-6.
10. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985;56:2765-70.
11. Nicolson GL, Custead SE. Effects of chemotherapeutic drug on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Research 1985;45:331-6.
12. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986;4:1405-17.
13. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients re-ceiving cisplatin. Ann Intern Med 1979;90:929-31.
14. Aitokallio-Tallberg A, Viinikka L, Ylikorkala O. Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment. Br J Cancer 1989;60:785-8.
15. Blöchl-Daum B, Pehamberger H, Kurz C, Kyrle PA, Wagner O, Müller M, Monitzer B, Eichler HG. Effects of cisplatin on urinary thromboxane B2 excretion. Clin Pharmacol Ther 1995;58:418-24.
16. van Genderen PJ, Prins FJ, Michiels JJ, Schror K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol 1999;104:438-41.
17. Born GVR. Aggregation of blood platelets adenosine diphosphatase and its reversal. Nature (London) 1962;194:927-9.
18. Caprino L, Antonetti F, Borrelli F, Morelli L. In vitro activity of urokinase on platelet function and on ADP-degradation by vascular tissue. Thromb Res 1982;27:447-56.
19. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998;91:484-90.
20. Kubisz P, Seghier F, Klener P, Holan J. Influence of cis-platinum on some platelet functions in vitro. Neoplasma 1983;30:391-4.
21. Karolak L, Chandra A, Khan W, Marks B, Peters WP, Greenberg CS, Hannun YA. High-dose chemotherapy-induced platelet defect: inhibition of platelet signal transduction pathways. Mol Pharmacol 1993;43:37-44.
22. Wachowicz B, Olas B. Changes of platelet cytoskeleton induced by cisplatin in relation to platelet activation. Biomed Lett 1995;52:181-90.
23. Olas B, Wachowicz B. Cisplatin-induced changes in biological activity of blood platelets: thiol-related mechanisms. Anti-cancer Drug 1996;7:476-82.
24. Wachowicz B. Inhibitory effect of cisplatin on the enzymatic peroxidation of platelet endogenous arachidonate. Cytobios 1993;75:157-62.
25. Softeland E, Framstad T, Thorsen T, Holmsen H. Porcine platelets in vitro and in vivo studies: relevance to human thrombosis research. Eur J Haematol 1992;49:161-73.
26. Poole AW. The study of platelet function in other species. In: Watson SP, Authi KS (editors). Platelets: a practical approach. New York: IRL Press; 1996. p. 341-50.
27. Hofmann SL, Prescott SM, Majerus PW. The effects of mepacrine and p-bromophenacyl bromide on arachidonic acid release in human platelets. Arch Biochem Biophys 1982;215:237-44.
28. Hashizume T, Taniguchi M, Sato T, Fujii T. Arachidonic acid liberation induced by phosphatidic acid endogenously generated from membrane phospholipids in rabbit platelets. Biochim Biophys Acta 1994;1221:179-84.
29. Wooten DK, Teague TK, McIntyre BW. Separation of integrin-dependent adhesion from morphological changes based on differential PLC specificities. J Leukoc Biol 1999;65:127-36.
30. Iorio P, Gresele P, Stasi M, Nucciarelli F, Vezza R, Nenci GG, Goracci G. Protein kinase C inhibitors enhance G-protein induced phospholipase A2 activation in intact human platelets. FEBS Letters 1996;381:244-8.
31. Sadzuka Y, Shoji T, Takino Y. Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 1992;43:1872-5.
32. Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radical in cisplatin-induced acute renal failure in rats. J Lab Clin Med 1998;131:518-26.
33. Olas B, Wachowicz B. Modulation of cisplatin toxicity in blood platelets by glutathione depletion. Anti-cancer Drug 1998;9:473-8.
34. 2 production in cisplatin-induced nephrotoxicity. Biochem Biophys Res Commun 1998;242:310-2.
35. Rashba-Step J, Tatoyan A, Duncan R, Ann D, Pushpa-Rehka TR, Sevanian A. Phospholipase peroxidation induces cytosolic phospholipase A2 activity: membrane effects versus enzyme phosphorylation. Arch Biochem Biophys 1997;343:44-54.
36. Schiess K, Kaszkin M, Jordan P, Seidler L, Kinzel V. Mobilization of diacylglycerol in in-tact HeLa cells by exogenous phospholipase C from Cl. Perfringens is accompanied by release of fatty acids including arachidonic acid. Biochim Biophys Acta 1992;1137:82-94.
37. Nishio K, Sugimoto Y, Fujiwara Y, Ohmori T, Morikage T, Takeda Y, Ohata M, Saijo N. Phospholipase C-mediated hydrolysis of phos-phatidylcholine is activated by cis-diamminedichloroplatinum (II). J Clin Invest 1992;89:1622-8.
38. DeConti RC, Toftness BR, Lange RC, Creasey WA. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 1973;33:1310-5.